Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Bristol-Myers Squibb (BMY) stock in plain English

Free brief · no signupStart here
BMYPublished Nov 7, 2026
Bristol-Myers Squibb Co
Healthcare · Drug Manufacturers - General
Manufactures and sells specialty prescription medicines for cardiovascular diseases, cancer, and immune disorders globally.
Assets:
Global manufacturing networkOperates biomanufacturing plants in Massachusetts, Ireland, and Puerto Rico.
34,000 employeesStaff runs clinical drug trials, laboratory research, and distribution across dozens of countries.
Cell therapy hubsMaintains specialized commercial cell therapy manufacturing centers in Washington and New Jersey.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
-2.05%$58.34
$119.25B
12.9×
$50.11B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 07, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BMY. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Bristol-Myers Squibb (BMY) do?

Bristol-Myers Squibb Co (BMY) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells specialty prescription medicines for cardiovascular diseases, cancer, and immune disorders globally. Discovers, manufactures, and distributes prescription biopharmaceutical medicines across oncology, immunology. It is worth $119.25B on the market and sold $50.11B over the last year.

Market cap
$119.25B
P/E ratio
12.9×
Annual sales
$50.11B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 07, 2026

Brands and businesses behind BMY

  • Eliquis: Prescription blood thinner that generates revenue through sales to treat and prevent blood clots and strokes.
  • Opdivo: Prescription immunotherapy medicine that generates revenue by treating various forms of advanced cancer.
  • Revlimid: Prescription oral cancer medicine that earns revenue from treating multiple myeloma and myelodysplastic syndromes.
  • Pomalyst: Prescription oral therapy that earns revenue by treating patients with relapsed or refractory multiple myeloma.
  • Yervoy: Prescription immune oncology drug that earns revenue by treating advanced melanoma and other malignant cancers.
  • Orencia: Prescription biologic therapy that generates revenue through treatments for rheumatoid and psoriatic arthritis.

BMY’s flags, in plain English

Each flag is a number from Bristol-Myers Squibb’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.

Earns Its Keep

Earns 44.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Wide Gross Margin

Gross margin of 66.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Cheap on Cash Flow

Priced at 12.8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Debt Is Driving

Heavy debt, 191% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about BMY

How big is Bristol-Myers Squibb?

Bristol-Myers Squibb’s market cap is $119.25B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $50.11B: what customers paid the company over the last year, before any costs.

What is BMY’s P/E ratio?

BMY’s P/E ratio is 12.9×. Investors pay about 12.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with BMY?

Key blockbuster medicines face generic market entry and government price negotiation, eroding revenue from Eliquis and Revlimid. That is one risk on Bristol-Myers Squibb’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Bristol-Myers Squibb’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BMY’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card